Navigation Links
Endocrine Society calls for large-scale studies to evaluate testosterone therapy risks
Date:2/7/2014

Chevy Chase, MDAccording to a statement issued today by the Endocrine Society, the risks and benefits of testosterone therapy for older men with declining levels of the hormone need to be fully evaluated.

The statement comes in response to recent studies that have raised concerns about the safety of testosterone therapy in older men with a history of heart disease. Two retrospective analyses and one randomized trial supported by the Veterans Health Care System, and the National Institutes of Health found a higher rate of cardiovascular events in men who received testosterone and had preexisting heart problems. The U.S. Food and Drug Administration has announced it plans to evaluate the safety of testosterone therapy.

Testosterone is approved for the treatment of hypogonadism due to known diseases of the testes, pituitary and hypothalamus. Although the use of testosterone therapy is increasing, the treatment has not been approved for the treatment of age-related symptoms or the age-related decline of testosterone levels.

Important safety data are expected from the NIA's ongoing randomized trial examining testosterone in about 800 older men with unequivocally low testosterone levels and accompanying symptoms, including sexual and physical dysfunction. The trial's structure and careful monitoring of cardiovascular events will help provide important safety information.

The Society calls for the development of more large-scale randomized controlled trials to determine the true risks and benefits of testosterone therapy in older men.

In the statement, the Society recommends that middle-aged and older men who are considering testosterone supplementation for age-related declines should be informed of the potential cardiovascular risks. The Society also believes that it may be prudent not to administer testosterone therapy to men who have had a cardiovascular event (such as myocardial infarction, stroke or acute coronary syndrome) in the preceding six months.

In cases where men are being treated for hypogonadism as a result of known diseases of the testes, pituitary and hypothalamus, however, patients should consult their health care providers before making any changes to their medication regimen. The Society believes testosterone is generally safe and beneficial when used to treat young, hypogonadal men with these conditions. The Society's Clinical Practice Guideline on testosterone therapy in this population is available at http://www.endocrine.org/~/media/endosociety/Files/Publications/Clinical%20Practice%20Guidelines/FINAL-Androgens-in-Men-Standalone.pdf.


'/>"/>

Contact: Jenni Glenn Gingery
jgingery@endocrine.org
301-941-0240
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Chemotherapy effective for patients with resected SCLC or large-cell neuroendocrine carcinoma
2. Simpler lifestyle found to reduce exposure to endocrine-disrupting chemicals
3. Imaging agents predict breast cancer response to endocrine therapy
4. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
5. Researchers craft tool to minimize threat of endocrine disruptors in new chemicals
6. UCLA study finds endocrine disorder is most common cause of elevated calcium levels
7. Endocrine Society announces 2014 Laureate Award winners
8. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
9. New American Chemical Society video: Behind the scenes tour of an electronic nose lab
10. The Gerontological Society of America Selects 2012 Fellows
11. Piramal imaging to present data at Society for Nuclear Medicine Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Mental health watchdog Citizens Commission ... Scientology and renowned professor of psychiatry Thomas Szasz, is continuing its protest against the ... of Death” exhibit in Atlanta, Georgia. The opening of the exhibit follows CCHR’s recent ...
(Date:5/24/2016)... ... May 24, 2016 , ... Boyd Industries, a leading supplier of ... a groundbreaking new product for pediatric dentistry , at AAPD 2016, the annual ... TX May 26-29. The Concealed Delivery Unit keeps dental hand pieces and other anxiety-provoking ...
(Date:5/24/2016)... ... 24, 2016 , ... The Radiosurgery Society (RSS), a non-profit ... recognizing five medical residents and students for their outstanding contributions to research in ... will be presented at the 2016 SRS/SBRT Scientific Meeting taking place June 16-18, ...
(Date:5/24/2016)... ... 2016 , ... As reported by MassGeneral.org, on May 8 – 9, 2016, ... States . The 64-year-old patient who received the transplant had undergone a partial penectomy ... a natural appearance, but also urinary and sexual function for the patient who has ...
(Date:5/24/2016)... ... May 24, 2016 , ... Harvard ... a licensing relationship that will deliver a new series of Q&A videos to ... the medical knowledge and expertise of Harvard Medical School faculty into brief videos ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... KONG , May 24, 2016 ... stent de doble terapia del mundo, introduce catéteres ... arteriovenosa. OrbusNeich, una compañía global especializada ... las vidas, ha expandido su cartera incluyendo productos ... balón JADE™ y Scoreflex™ PTA son los dispositivos ...
(Date:5/24/2016)... May 24, 2016 Open Access ... Clinical Neurophysiology  Elsevier , a world-leading ... services, today announced the launch of Clinical ... journal that focuses on clinical practice issues in clinical ... clinical series, normal values and didactic reviews. It is ...
(Date:5/24/2016)... , May 24, 2016 ... elkaar verbindt, zodat zij collectief patiënten kunnen behandelen, hun ... is het idee achter de nieuwe en revolutionaire MDLinking ... van de Nederlandse vaatchirurg dr. Hans Flu en oncologisch ... app, die inmiddels beschikbaar is, wordt op dinsdag 24 ...
Breaking Medicine Technology: